Free Trial
→ What the hell is going on? (From Porter & Company) (Ad)tc pixel
OTCMKTS:SQZB

SQZ Biotechnologies Q1 2023 Earnings Results & Report

$0.02 0.00 (0.00%)
As of 11/9/2026

SQZ Biotechnologies missed analyst earnings expectations in its Q1 2023 results, released May 10, 2023. The company reported EPS of -$0.60 versus the -$0.54 consensus estimate.

Research:Profile

Earnings Announcement Details

Quarter
Q1 2023
Report Date

SQZ Biotechnologies EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.54
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

SQZ Biotechnologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

SQZ Biotechnologies' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

SQZ Biotechnologies Q1 2023 Earnings FAQ

SQZ Biotechnologies (OTCMKTS:SQZB) reported earnings of -$0.60 per share for Q1 2023, missing the consensus estimate of -$0.54. The report was announced on Wednesday, May 10, 2023.

SQZ Biotechnologies' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for SQZ Biotechnologies on the company's earnings history page.

SQZ Biotechnologies Earnings Headlines

SQZ Biotechnologies (SQZB) Projected to Release Quarterly Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180054
SQZ founder's new startup goes from zero to $1M in revenue in a year
December 19, 2024  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2024/12/19/portal-bio-seed-round.html
Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.tc pixel
November 10 at 1:00 AM  |  Porter & Company (Ad)
SQZ Biotechnologies (OTC:SQZB) Stock, Short Interest Report
October 6, 2024  |  benzinga.comhttps://www.benzinga.com/quote/SQZB/short-interest
Introducing Portal Biotechnologies
December 12, 2023  |  businesswire.comhttps://www.businesswire.com/news/home/20231212550177/en/Introducing-Portal-Biotechnologies
See More SQZ Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SQZ Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SQZ Biotechnologies and other key companies, straight to your email.

About SQZ Biotechnologies

SQZ Biotechnologies (OTCMKTS:SQZB) Co. was a biotechnology company that developed cell therapies using its proprietary Cell Squeeze technology. The platform was designed to deliver biological materials, including proteins, nucleic acids and other therapeutic payloads, directly into cells while preserving cell viability and function.

The company focused primarily on oncology and immunology applications. Its research programs included engineered immune-cell therapies intended to stimulate anti-tumor responses, including programs involving antigen-presenting cells and peripheral blood mononuclear cells. SQZ Biotechnologies also evaluated potential applications in infectious diseases and other conditions involving immune-system regulation.

Founded in 2013 and headquartered in Cambridge, Massachusetts, the company conducted research and development activities in the United States. Armon Sharei, a co-founder, served as its chief executive officer for much of its public-company history. SQZ Biotechnologies later announced plans to wind down its operations, and publicly available information about its ongoing business activities is limited.

View SQZ Biotechnologies Profile
Earnings Tools